May. 12 at 10:14 PM
$ENTX A lot happening over the next few months. FDA feedback on the phase III trial protocol for EB613 soon. Next month data for both EB612 and EB618 at ENDO2026 conference... IND for EB612 in second half of the year and then the count down to the start of phase III for EB613, the first, best and only oral anabolic for bone building for osteoperosis... recall that Forteo peaked at
$1.7B in sales despite only serving a small percentage of Osteoperosis patients because most patients weren't willing to get an injection... EB613 solves that problem.
